{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:00:06Z","timestamp":1763398806645,"version":"3.37.3"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Antipsychotics can cause hematologic disorders, and they can have life-threatening\n        consequences. Risperidone, less commonly associated with hematologic adverse\n        effects, is an atypical antipsychotic medication used to treat conditions such as\n        schizophrenia, bipolar disorder and irritability associated with autism. While\n        risperidone primarily affects the central nervous system, it can have some\n        hematologic adverse effects, although these are relatively rare. It is crucial to\n        note that these side effects are not common, and most people taking risperidone do\n        not experience hematologic disorders. The reporting of such disorders may be more\n        frequent with clozapine compared to other atypical antipsychotics because clozapine\n        treatment necessitates regular hematological monitoring 1.<\/jats:p>","DOI":"10.1055\/a-2262-8297","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T23:37:11Z","timestamp":1710286631000},"page":"78-81","source":"Crossref","is-referenced-by-count":3,"title":["Risperidone-Induced Leukoneutropenia: Evidence from a Positive\n                    Rechallenge and Review of the Literature"],"prefix":"10.1055","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-2667","authenticated-orcid":false,"given":"Dhouha","family":"Sahnoun","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, University of Sousse,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlem","family":"Ghanmi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Farhat Hachad Hospital, Sousse University,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumaya","family":"Gazzeh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Farhat Hachad Hospital, Sousse University,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bochra","family":"Saguem","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Farhat Hachad Hospital, Sousse University,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoudha","family":"Slim","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, University of Sousse,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaafar","family":"Nakhli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Farhat Hachad Hospital, Sousse University,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaker","family":"Ben Salem","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, University of Sousse,\n                    Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of\n                    haematological malignancies in people with schizophrenia: a nationwide\n                    case-control and cohort study in Finland","volume":"9","author":"J Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"C A Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0033-3182(99)71206-5","article-title":"Hematologic side effects of psychotropics","volume":"40","author":"O Oyesanmi","year":"1999","journal-title":"Psychosomatics."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1055\/s-2004-815513","article-title":"Blood dyscrasias induced by psychotropic drugs","volume":"37","author":"S St\u00fcbner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-977X(94)00125-U","article-title":"Reversible neutropenia during a cold: possible involvement of risperidone? A\n                    case report","volume":"5","author":"C Meylan","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0924-977X(96)00024-7","article-title":"Risperidone and reversible neutropenia: a negative rechallenge","volume":"6","author":"G Bondolfi","year":"1996","journal-title":"Eur Neuropsychopharmacol J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.171.4.393d","article-title":"Risperidone-induced leucopenia and neutropenia","volume":"171","author":"Z Dernovsek","year":"1997","journal-title":"Br J Psychiatry"},{"key":"ref8","first-page":"81","article-title":"A case of leukopenia in treatment with risperidone in an adolescent","volume":"26","author":"B Etain","year":"2000","journal-title":"L\u2019Encephale"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eurpsy.2003.03.009","article-title":"Risperidone-induced leucopenia and neutropenia: a case report","volume":"19","author":"M Sluys","year":"2004","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1157\/13086216","article-title":"Leukopenia associated to the use of risperidone: a case report and review of the\n                    literature","volume":"206","author":"F X L\u00f3pez Altimiras","year":"2006","journal-title":"Rev Clin Esp"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/JCP.0b013e31818b53a1","article-title":"Leukopenia during therapy with risperidone long-acting injectable: two case\n                    reports","volume":"28","author":"S Uzun","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref12","first-page":"243","article-title":"The risperidone-induced leukopenia and neutropenia: A case at 7 years old","volume":"12","author":"F Erbey","year":"2011","journal-title":"Anadolu Psikiyatri Dergisi"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1176\/jnp.23.4.jnpe19","article-title":"Neutropenia during risperidone treatment","volume":"23","author":"C C Tseng","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"102.e3","DOI":"10.1016\/j.genhosppsych.2012.03.009","article-title":"Risperidone-induced leukopenia: a case report and brief review of\n                    literature","volume":"35","author":"G Manfredi","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/bmjspcare-2012-000348","article-title":"Risperidone-induced neutropenia: an adverse side effect in the palliative\n                    management of delirium in a patient with lymphoma","volume":"3","author":"H Farrell","year":"2013","journal-title":"BMJ Support Palliat Care"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0004867412460594","article-title":"Risperidone\/paliperidone induced neutropenia and lymphopenia","volume":"47","author":"V Raj","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1176\/appi.neuropsych.13070162","article-title":"The relief of leukocytopenia within 1 month after switching risperidone to\n                    amisulpride","volume":"26","author":"Y C Hou","year":"2014","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2147\/NDT.S141472","article-title":"Risperidone-induced reversible neutropenia","volume":"13","author":"V Kattalai Kailasam","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PRA.0000000000000292","article-title":"Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic\n                    Adverse Reaction?","volume":"24","author":"LS C Woon","year":"2018","journal-title":"J Psychiatr Pract"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"19l02516","DOI":"10.4088\/PCC.19l02516","article-title":"Successful Long-Acting Paliperidone Treatment Following Reversible\n                    Risperidone-Induced Neutropenia","volume":"22","author":"P R McGuire","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref21","first-page":"3980872","article-title":"Risperidone-Induced Neutropenia in a Schizophrenic Patient: A Case Report and\n                    Literature Review","volume":"2021","author":"A Atolagbe","year":"2021","journal-title":"Case Rep Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/JCP.0b013e31820e3d9d","article-title":"Does switching to another antipsychotic in patients with clozapine-associated\n                    granulocytopenia solve the problem? Case series of 18 patients","volume":"31","author":"B Co\u015far","year":"2011","journal-title":"J ClinPsychopharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry","volume":"23","author":"R J Flanagan","year":"2008","journal-title":"Human Psychopharmacology: Clinical and Experimental"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2262-8297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:55:10Z","timestamp":1730811310000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2262-8297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,3,12]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2262-8297","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}